



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FEB 24 2006

Re: Relpax
Docket No.: 2003E-0146

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 5,545,644, filed by Pfizer, Inc., under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Relpax, the human drug product claimed by the patent.

The total length of the regulatory review period for Relpax is 2,829 days. Of this time, 1,307 days occurred during the testing phase and 1,522 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: March 31, 1995.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on March 31, 1995.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: October 27, 1998.

FDA has verified the applicant's claim that the new drug application (NDA) for Relpax (NDA 21-016) was initially submitted on October 27, 1998.


3. The date the application was approved: December 26, 2002.

FDA has verified the applicant's claim that NDA 21-016 was approved on December 26, 2002.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" being the most prominent.

Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

cc: A. David Joran
Pfizer, Inc.
Legal Division
150 East 42nd Street
New York, NY 10017-5755